Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab

Subcutaneous (SC) trastuzumab has long been approved as a cancer treatment for early and advanced HER2-positive (HER2+) breast cancer by both the European Medicines Agency (EMA) and Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian National Health Surveillance Agency. A pivotal non-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimentel, Franklin Fernandes, Morgan, Gilberto, Tiezzi, Daniel Guimarães, de Andrade, Jurandyr Moreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182492/
https://www.ncbi.nlm.nih.gov/pubmed/30363808
http://dx.doi.org/10.1007/s40290-018-0247-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182492/
https://www.ncbi.nlm.nih.gov/pubmed/30363808
http://dx.doi.org/10.1007/s40290-018-0247-5

Ejemplares similares